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Summary
 
The mechanisms that establish immune tolerance in immature and mature B cells appear to be
distinct. Membrane-bound autoantigen is thought to induce developmental arrest and receptor
editing in immature B cells, whereas mature B cells have shortened lifespans when exposed to
the same stimulus. In this study, we used E
 
m
 
–
 
bcl
 
-
 
2
 
-22 transgenic (Tg) mice to test the predic-
tion that enforced expression of the Bcl-2 apoptotic inhibitor in B cells would rescue mature,
but not immature, B cells from tolerance induction. To monitor tolerance to the natural mem-
brane autoantigen H-2K
 
b
 
, we bred 3–83
 
md
 
 (anti-K
 
k,b
 
) Ig Tg mice to H-2
 
b
 
 mice or to mice ex-
pressing transgene-driven K
 
b
 
 in the periphery. In 3–83
 
md
 
/
 
bcl-2
 
 Tg mice, deletion of autoreac-
tive B cells induced by peripheral K
 
b
 
 antigen expression in the liver (MT-K
 
b
 
 Tg) or epithelia
(KerIV-K
 
b
 
 Tg), was partly or completely inhibited, respectively. Furthermore, Bcl-2 protected
peritoneal B-2 B cells from deletion mediated by acute antigen exposure, but this protection
could be overcome by higher antigen dose. In contrast to its ability to block peripheral self-tol-
erance, Bcl-2 overexpression failed to inhibit central tolerance induced by bone marrow anti-
gen expression, but instead, enhanced the receptor editing process. These studies indicate that
apoptosis plays distinct roles in central and peripheral B cell tolerance.
 
A
 
poptosis is an essential element in the development and
homeostasis of many tissues. In the immune system, a
number of important processes are regulated through the
control of cell death and survival (1–4). Among these pro-
cesses is immunological tolerance in which encounter with
ligands that signal through antigen receptors affect the cell’s
subsequent survival (5, 6). The lifespans of lymphocytes in
vivo vary widely, from 1–2 d to many weeks (7). Self-antigen
can shorten the lifespan of reactive B cells in a number of
ways: by promoting cell death through developmental arrest
(8, 9), by increasing cell turnover (10, 11), by putting cells
at a competitive disadvantage with nonautoreactive cells for
unknown resources (12), by making the cells sensitive to Fas
ligand–mediated killing by T cells (13), or apparently through
direct induction of apoptosis (11, 14–18).
One regulator of lymphocyte survival is the Bcl-2
protein (1), which is highly expressed in long-lived lym-
phocytes and is poorly expressed in cells destined to turn
over rapidly (19–26). Bcl-2, and the closely related Bcl-x
 
L
 
(27), are key protein regulators of apoptosis. Overexpres-
sion or inappropriate expression of these proteins can play
a role in lymphoma development and can allow the con-
tinued survival of cells that would otherwise be lost through
apoptosis (28–36). However, some forms of apoptosis, in-
cluding Fas-mediated killing of certain lymphoid cells (37),
are not inhibitable by Bcl-2. An important physiological
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role for Bcl-2 is evident from the phenotype of 
 
bcl-2
 
–defi-
cient mice, which manifest a catastrophic apoptotic loss of
mature lymphocytes (38, 39).
The ability of Bcl-2 to block B cell tolerance has been
studied in several systems in which ligands that bind to the
B cell receptor (BCR)
 
1
 
 can stimulate cell death in vivo or
in vitro (9, 15, 33, 40–48). In some cases, these data have
been contradictory, suggesting that the ability of Bcl-2 over-
expression to block tolerance-mediated apoptosis may be
contingent upon the precise quality of the BCR-mediated
signal and perhaps other signals that may differ in certain
experimental systems. In the well-characterized surface Ig
 
1
 
 B
lymphoma WEHI-231, cross-linking of the BCR with an-
tiimmunoglobulin antibody leads to cell death (for review
see reference 18). In some studies (43, 44), but not others
(40), transfection of 
 
bcl-2
 
 expression constructs protected the
cells from BCR-mediated cell death. When transgenic (Tg)
mice with enforced B cell overexpression of Bcl-2 were
analyzed for B cell tolerance, bone marrow tolerance was
perturbed in one study (9), but not in another (46),
whereas peripheral tolerance was inhibited (15, 46). Simi-
larly, germinal center B cells have been shown to be sensi-
tive to killing induced by acute ligation of sIg, and this
death could be inhibited by enforced Bcl-2 expression in
one study (48), but not in another (47). These studies and
others focusing on T cell tolerance (3, 4) have suggested
that the ability of Bcl-2 to protect autoreactive lymphocytes
from cell death may be contingent upon many factors, in-
cluding the developmental stage of the lymphocyte as well
as the nature of the antigen stimulus.
Resting B cells encountering tissue-specific membrane-
bound antigen in the periphery are eliminated, suggesting
that in this case, peripheral tolerance is mediated by an
apoptotic process (14). In contrast, it has been shown in
several systems that immature B cells encountering mem-
brane-bound or nuclear self-antigens in the bone marrow
are blocked in their development (8, 9) and either undergo
receptor editing (49, 50) or are eliminated (50–52). Our re-
cent finding that in vitro tolerance induction of immature
B cells stimulates intense receptor editing with little imme-
diate cell death (53, 54) suggests that antigen-induced pro-
grammed cell death makes only a minor contribution to
central tolerance. Assuming that Bcl-2 is a key cell death
regulator in B cells, this model predicts that enforced Bcl-2
expression can block clonal elimination of mature, but not
immature, self-reactive B cells. To test this, peripheral and
central tolerance in 3–83
 
md
 
 (anti–H-2
 
k,b
 
) Ig Tg mice were
compared to that occurring in 3–83
 
md
 
/E
 
m
 
–
 
bcl-2
 
-22 dou-
ble-Tg mice, in which Bcl-2 is constitutively expressed in
B-lineage cells.
 
Materials and Methods
 
Mice.
 
MT-K
 
b
 
 mice, in which K
 
b
 
 antigen expression is di-
rected to hepatocytyes by the sheep metallothionein promoter
(55), and KerIV-K
 
b
 
 mice, in which K
 
b
 
 is expressed in epithelial
cells under the control of the keratin IV promoter (56), were bred
several generations onto the B10.D2 background (H-2
 
d
 
) before
breeding with other Tg or H-2 congenic mice. 3–83
 
md
 
 Tg mice,
which express IgM and IgD forms of the 3–83 antibody, have been
described (14). 3–83
 
md
 
 mice were backcrossed a minimum of 10
times onto the B10.D2 background. C57BL/6(H-2
 
b
 
), C3H-H-
2
 
o2
 
/SfSn (C3H.OH: K
 
d
 
D
 
k
 
), and B10.D2/nSnJ (H-2
 
d
 
) mice were
purchased from Jackson Laboratory (Bar Harbor, ME). Mice
overexpressing the human 
 
bcl-2
 
 gene in B-lineage cells were Tg lines
E
 
m
 
–
 
bcl-2
 
-22 (34) and 
 
bcl-2
 
-Ig NL (36). These mice were back-
crossed a minimum of three generations to B10.D2 and subse-
quently bred with 3–83
 
md
 
 Tg mice. The phenotypes of mice
bearing either of the 
 
bcl-2
 
 transgenes were indistinguishable in our
study. Unless otherwise stated, the experiments described made use
of the E
 
m
 
–
 
bcl-2
 
-22 line. The 3–83
 
md
 
/RAG-1 knockout mice (57)
were bred with E
 
m
 
–
 
bcl-2
 
-22 Tg mice. F
 
2
 
 crosses were set up to
generate 
 
bcl-2
 
/3–83
 
md
 
/RAG-1
 
2
 
/
 
2
 
 mice with all transgenes hemi-
zygous except where noted. All mice were bred and maintained
under specific pathogen-free conditions in the animal care facility
at the National Jewish Medical and Research Center (NJMRC,
Denver, CO).
 
Mouse Typing.
 
PCR typing for 3–83
 
md
 
, K
 
b
 
, and 
 
bcl-2
 
 trans-
genes was as described previously (14). RAG-1–deficient mice
were identified by their lack of T cells in flow cytometric analysis
of peripheral blood.
 
Antibodies, Immunofluorescence, Cell Lines, and Intraperitoneal In-
jection Assays.
 
Preparation of lymphoid cells, antibody reagents,
fluorochrome conjugation, flow cytometry analysis, cell lines, and
intraperitoneal injection assay methods were as previously de-
scribed (58). In brief, the A/J splenocyte 
 
3
 
 Sp2/0 hybridoma
4549 (which expresses K
 
k
 
) and Sp2/0 (H-2
 
d
 
) parent hybridoma
were washed and resuspended at either 5 
 
3
 
 10
 
7
 
 or 5 
 
3
 
 10
 
8
 
 cells/ml
in PBS and injected intraperitoneally into 3–83
 
md
 
/H-2
 
d
 
 or
3–83
 
md
 
/H-2
 
d
 
/
 
bcl-2
 
 Tg mice. Approximately 16 h later, the peri-
toneal cells were harvested with 10 ml HBSS, washed twice, and
stained for the presence of Id-reactive antibodies.
 
Cell Culture.
 
Spleen or lymph node cells were cultured in
RPMI-1640 medium supplemented with 10% FCS and 50 
 
m
 
M
2-mercaptoethanol 
 
6
 
 50 
 
m
 
g/ml LPS (Sigma Chemical Co., St.
Louis, MO). The cell concentration was adjusted depending on
the number of 3–83 B cells in the organ according to the follow-
ing guidelines: 10
 
6
 
 cells/ml for H-2
 
d
 
 3–83 Tg, H-2
 
d
 
 
 
bcl-2
 
/3–83
double-Tg, and 
 
bcl-2
 
/3–83
 
md
 
/KerIV-K
 
b
 
 triple-Tg mice; and 3–5
 
3
 
 10
 
6
 
 cells/ml for H-2
 
b
 
 3–83 Tg, H-2
 
b
 
 
 
bcl-2
 
/3–83
 
md
 
, 3–83/
MT-K
 
b
 
, 3–83/KerIV-K
 
b
 
 double-Tg, and 
 
bcl-2
 
/3–83
 
md
 
/MT-K
 
b
 
triple-Tg mice. In some experiments, lymph node and spleen cells
were T cell depleted with anti-Thy1 antibodies and rabbit com-
plement and cultured at 5 
 
3
 
 10
 
5
 
 cells/ml. Culture supernatants
were harvested on days 3 and 7 after initiation of culture and Ig
concentrations determined by ELISA, as described (14).
 
5-bromo-2
 
9
 
-deoxyuridine Incorporation Assay.
 
5-bromo-2
 
9
 
-deox-
yuridine (BrdU; Sigma Chemical Co.) was provided in filtered,
deionized drinking water at a concentration of 1 mg/ml for 7 d.
Staining for the incorporation of BrdU was described previously (59).
 
Results
 
Enforced Bcl-2 Expression Blocks B Cell Deletion Induced by
Acute Antigen Administration at Low Dose, but Not at High
Dose.
 
The 3–83
 
md
 
 Ig transgene encodes a BCR that is
reactive to a number of MHC class I alloforms including
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell receptor; BrdU, 5-bromo-2
 
9-
deoxyuridine; CD, central deleting; ND, nondeleting; Tg, transgenic.1515 Lang et al.
Kk, Dk, and Kb, but fails to bind to H-2d; thus, 3–83md/H-2d
mice contain a virtually monoclonal B cell population
bearing the 3–83 BCR and are called nondeleting (ND)Tg
mice (14). To probe the ability of enforced Bcl-2 expres-
sion to block tolerance to acute intraperitoneal antigen chal-
lenge, we injected NDTg and NDTg/bcl-2 mice with anti-
gen-bearing cells, a protocol that stimulates rapid apoptosis
of fully mature antigen-specific peritoneal B cells (15, 16).
Injection of hybridoma cells bearing the high-affinity Kk anti-
gen consistently led to massive loss (z80%) of the 3–83md
peritoneal B cells over a 16-h period, whereas injection of
control H-2d cells did not (Fig. 1). At low antigen dose (5 3
106 cells), NDTg/bcl-2 B cells resisted deletion induced by
the Kk antigen (Fig. 1); however, this protection from death
afforded by Bcl-2 overexpression was overcome with a 10-
fold increased antigen dose (Fig. 1).
Enforced Bcl-2 Expression Partially Blocks B Cell Deletion
Induced by Hepatocyte-targeted Kb and Completely Blocks B Cell
Deletion Induced by Epithelial Cell–targeted Kb. To study
peripheral B cell tolerance to natural chronic autoantigen
exposure, we generated 3–83md mice bearing MT-Kb or
KerIV-Kb transgenes, which target cell surface expression of
the Kb protein to hepatocytes or epithelia, respectively (55,
56). Relative to antigen-free mice, antigen-bearing 3–83md
mice had profoundly reduced B cell numbers in the lymph
nodes (Fig. 2 A, top; Fig. 2 B, compare H-2d to MT-Kb and
KerIV-Kb), and substantial, but on average, incomplete de-
letion of the B cells in the spleen (Fig. 2 C, top; Fig. 2 D
and reference 14). Control mice bearing antigen on all tis-
sues (Fig. 2, H-2b) exhibited the phenotype of central B cell
tolerance in which antigen-reactive cells were absent from
the spleen. In the mice that demonstrated peripheral B cell
deletion (3–83md/MT-Kb or 3–83md/KerIV-Kb), the re-
maining splenic cells manifested rapid turnover as assessed
by their BrdU uptake over a 1-wk labeling period (Fig. 3).
It is important to note that the MT-Kb/3–83md mice
showed a more profound tolerance than KerIV-Kb/3–
Figure 1. Enforced Bcl-2 expression inhibits B cell deletion induced by
acute challenge with membrane antigen in an antigen dose–dependent
manner. NDTg and NDTg/bcl-2 mice were injected intraperitoneally
with either PBS control, Kk-expressing tumor cells, or Kd tumor cells, and
the peritoneal cells were analyzed 16 h later for the loss of 3–83 B cells us-
ing 54.1 anticlonotype and anti-IgM antibodies. The data from three ex-
periments are presented as mean 6 SEM. In some data points, error bars
are not apparent because of their small range.
Figure 2. Enforced Bcl-2 ex-
pression blocks peripheral clonal
deletion in 3–83md mice. (A
and  C) 3–83md Tg mice (top) or
3–83md/ bcl-2 Tg mice (bottom)
bearing the indicated self-anti-
gens were analyzed for Id1 B
cells in lymph node (A) and
spleen (C). (B and D) The com-
piled FACSÒ data as percentage
of IgM1/Id1 cells in the lym-
phoid analysis gate is shown.
Data are presented as mean 6
SEM. The numbers below each
bar represent the number of
mice analyzed per group.1516 Effect of Bcl-2 Overexpression on Immature and Mature B Cell Tolerance
83md mice, and had more complete elimination of Id1 B
cells in the lymph nodes (Fig. 2) and of Id1 antibodies in
the serum (Fig. 4 C).
In  bcl-2/3–83md/MT-Kb and bcl-2/3–83md/KerIV-Kb
triple-Tg mice, enforced Bcl-2 expression partially or com-
pletely blocked peripheral B cell deletion to liver and skin
antigens, respectively, and, on average, increased numbers
of Id1 cells in both the lymph nodes and spleen (Fig. 2, A
and C, bottom; Fig. 2, B and D). Interestingly, in the bcl-2/
3–83md/MT-Kb mice in which Bcl-2 protection was par-
tial, the high rate of turnover of the autoreactive B cells was
unchanged, whereas in the bcl-2/3–83md/KerIV-Kb triple-
Tg mice in which B cell deletion was effectively blocked,
B cell turnover was also normalized, and only z20% of the
B cells had incorporated BrdU over a 1-wk period (Fig. 3).
Furthermore, lymph node cells from bcl-2/3–83md/KerIV-Kb
triple-Tg, but not those from bcl-2/3–83md/MT-Kb mice, ac-
quired the ability to respond to LPS stimulation (Fig. 4 A).
The ability of lymph node and spleen cells to secrete 3–83
antibodies in vitro was consistent with the levels of 3–83
antibodies measured in the sera of these mice, as Id1 anti-
body levels were negligible in the bcl-2/3–83md/MT-Kb
mice, but were significant in the bcl-2/3–83md/KerIV-Kb
triple-Tg mice (Fig. 4 C). The only differences noted be-
tween bcl-2/3–83md/KerIV-Kb triple-Tg mice and bcl-2/
3–83md ND controls were a consistent twofold reduction
in surface IgM expression in the bcl-2/3–83md/KerIV-Kb
mice, suggesting antigen encounter that did not result in
deletion (Fig. 2, A and C), and a lower percentage of cells
expressing CD21 (data not shown). In both bcl-2/3–83md/
KerIV-Kb and bcl-2/3–83md/MT-Kb mice, the B2201 B cells
coexpressed the maturation marker CD23 (data not shown).
Collectively, these data demonstrated that Bcl-2 overex-
pression could inhibit peripheral B cell tolerance to both
acute and chronic antigen exposure, but the degree of pro-
tection varied depending upon the dose or anatomical lo-
cation of the antigenic stimulus.
Enforced Bcl-2 Expression Does Not Block Central B Cell
Tolerance. The Em–bcl-2-22 transgene drives expression of
functionally active Bcl-2 in immature bone marrow B cells
that normally lack Bcl-2 expression (46). To test the effect
of this transgene on central B cell tolerance, we bred H-2b
mice to 3–83md and bcl-2/3–83md mice, generating central
deleting (CD)Tg and CDTg/bcl-2 mice, respectively. Like
CDTg mice, CDTg/bcl-2 mice lacked Id1 B cells in the
peripheral lymphoid organs (Fig. 2, H-2b; Table 1) and Id1
antibodies in the sera (Fig. 4 C). In addition, no Id1 anti-
bodies were found in the supernatants of LPS-stimulated
spleen cells from CDTg or CDTg/bcl-2 mice, whereas NDTg
and NDTg/bcl-2 controls had significant levels of Id1 anti-
bodies in both the sera and LPS culture supernatants (Fig. 4 A;
Figure 3. Effect of bcl-2 transgene on B cell turnover in peripheral anti-
gen-expressing 3–83md Tg mice. Mice were fed BrdU-containing water
for 7 d followed by staining of isolated lymph node and spleen cells with
anti-BrdU and anti-B220 antibodies. Data are presented as percentage
(mean  6 SEM) of B2201 cells that were BrdU positive. Numbers of mice
analyzed are indicated below bars. Mice lacking antigen were H-2d ND
controls.
Figure 4. In vitro and in vivo analysis of antibody secretion. Lymph
node and spleen cells from mice of the indicated genotypes were cultured
in the presence or absence of 50 mg/ml LPS. After 3 d of culture, super-
natants were analyzed by ELISA for Id1 (A) and IgM (B) antibodies. An-
tibody amounts were quantitated using 3–83 IgM transfectoma superna-
tant control. Similarly, Id1 ( C ) and IgM (D) serum antibodies were
quantitated by ELISA. Data are presented as mean 6 SEM with number
of mice (n) analyzed shown. The table below the graph shows Tg geno-
types (3–83, bcl-2, MT-Kb, and/or KerIV-Kb) and H-2 haplotypes (d, no
antigen; b, antigen). In C and D the RAG-1 genotype of analyzed mice
(1/1 or 2/2) is indicated.1517 Lang et al.
data not shown). Since previous central tolerance studies
investigating Bcl-2 overexpression used high-affinity anti-
gens (KA z109 M21), we tested whether or not Bcl-2 over-
expression had perhaps a subtle, antigen affinity-dependent
effect on tolerance induction by generating CDTg/bcl-2 mice
expressing the Dk class I molecule to which 3–83 has very
low affinity (KA z104 M21; reference 58). Again the CDTg/
bcl-2 mice had no detectable increase of Id1 B cells in the
peripheral lymphoid organs (Fig. 5) nor IgM idiotype in
the serum (data not shown).
Bcl-2 Overexpression Allows Survival of a Population of Tol-
erant, Immature IgM2, B2201 B Cells in the Peripheral Lymph
Organs. In some CDTg/bcl-2 mice (13/21), a population
of IgM2, B2201 B cells was detected in the spleen and, to a
lesser extent, in the lymph nodes. To further characterize
this population in a context in which receptor editing
could not occur, we generated CDTg/bcl-2/RAG-1–defi-
cient mice (57). Again, no strongly Id1 cells were detected
in the peripheral lymphoid organs (Fig. 6 A; Table 1), but a
significant population of IgM2, B2201, Idlo cells was de-
tected in the spleen of the CDTg/bcl-2/RAG-12/2 mice
(Fig. 6, A and B, note arrows), and a similar population was
detected to a lesser extent in CDTg/RAG-12/2 mice
without Bcl-2 overexpression. These IgM2, B2201 cells
were CD232, klo, IgDlo, and CR1/22 (data not shown)
which is indicative of immature B cells as has been previ-
ously reported in Bcl-2 overexpressing Ig Tg mice (9). Also
Figure 5. Enforced Bcl-2 expression fails to block central deletion in-
duced by the ultralow affinity 3–83 ligand Dk. Lymph node and spleen
cells from mice of the indicated genotypes were double stained for the
presence of B cells bearing the 3–83 Tg BCR with 54.1 anti-Id and anti-
IgM antibodies. The substantial population of IgM1 B cells present in the
CDTg mice were clonotype2 and are presumably the result of receptor
editing. The large percentage of B cells in the ND control in this experi-
ment reflects the RAG deficiency of this particular mouse.
Figure 6. Appearance of immature B cells in spleen of CD (H-2b) bcl-
2/RAG-1–deficient mice. Spleen cells from mice of the indicated geno-
types were stained for presence of 3–83 B cells with anticlonotype (54.1)
and anti-IgM antibodies (A), and anti-IgM and anti-B220 antibodies (B).
The immature B cells have low levels of Id and lack detectable sIgM (ar-
rows). The NDTg control used in this particular experiment was 3–83md
homozygous, which consistently show reduced B cell populations. Data
shown represent one of five similar experiments.
Table 1. Effect of Bcl-2 Overexpression on Tolerance Induction and Receptor Editing in 3-83 Immunoglobulin Transgenic Mice
Lymph Node Spleen
Genotype 54.11 IgDa, l1 B2201, IgM2 54.11 IgDa, l1 B2201, IgM2
Cell content (3 105)
NDTg 1/1 82 6 16 (12) 0.6 6 0.2 (11) 1.6 6 0.4 (10) 280 6 38 (11) 1.8 6 0.7 (11) 9.9 6 2.5 (11)
NDTg/bcl-2 1/1 160 6 40 (9) 1.6 6 0.4 (9) 6.3 6 1.2 (9) 350 6 70 (9) 4.4 6 1.3 (9) 17 6 7 (9)
NDTg 2/2 30 6 2 (2) 0 (1) 0.7 6 0.7 (2) 230 6 40 (3) 0.7 6 0.3 (2) 15 6 7 (3)
NDTg/bcl-2 2/2 580 (1) 0 (1) 2.1 (1) 870 (1) 0 (1) 5.3 (1)
CDTg 1/1 0.3 6 0.1 (19) 3.3 6 0.6 (19) 2.3 6 0.4 (17) 5.8 6 1.2 (19) 36 6 5 (20) 31 6 8 (19)
CDTg/bcl-2 1/1 0.6 6 0.2 (19) 14 6 3 (18) 9.9 6 2.5 (16) 6.1 6 1.7 (17) 66 6 19 (19) 57 6 17 (17)
CDTg 2/2 0.1 6 0.1 (5) 0.1 6 01 (3) 3.8 6 1.4 (5) 1.9 6 1.2 (5) 0 6 0 (4) 45 6 15 (5)
CDTg/bcl-2 2/2 0.8 6 0.4 (6) 0.1 6 0.1 (4) 11 6 6 (6) 5.3 6 3.3 (6) 0.2 6 0.2 (5) 160 6 28 (6)
Absolute number of idiotype-positive (54.11), “edited” (IgDa, l1), and immature (B2201, IgM2) B cells in 3-83 immunoglobulin transgenic mice
in the presence (CDTg) or absence (NDTg) of antigen in the bone marrow. In the genotype column 1/1 refers to normal levels of RAG-1 whereas
2/2 refers to RAG-1 homozygous knock-out mice. All numbers shown are averages 6 SEM divided by 105. The numbers in parenthesis refer to
sample size.1518 Effect of Bcl-2 Overexpression on Immature and Mature B Cell Tolerance
indicative of immature B cells, these cells expressed RAG-2
messenger RNA transcripts (data not shown). These cells
failed to secrete antibodies in LPS cultures and in vivo, as
no antibodies were detected in the serum (Fig. 4 C). In
CDTg/RAG-12/2 mice, no serum IgM was detected be-
cause RAG deficiency prevented development of Id2 B cells
(Fig. 4 D). These splenic immature B cells were short lived,
as z50% of the cells had incorporated BrdU1 after 1 wk
compared to only z20% of B2201 cells from non-Tg or
NDTg mice (data not shown). Thus, in contrast to its ef-
fect on peripheral tolerance, the bcl-2 transgene appeared to
have only a subtle effect on central B cell tolerance, allow-
ing a subset of autoreactive nonfunctional, immature B cells
to survive in the spleen for a short time.
Enforced Bcl-2 Expression Increases the Number of Id2 B
Cells. Bcl-2 overexpression increased the numbers of
nonautoreactive, Id2 B cells that developed in CD H-2b/
3–83md Tg mice by two- to fivefold (Fig. 7 B; Table 1). In
contrast to the results with the mice bearing antigen tar-
geted to peripheral tissues in which autoreactive B cells
with enforced Bcl-2 expression were spared, the B cells ap-
pearing in the spleen and lymph nodes of CDTg/bcl-2 mice
were nonautoreactive and had undergone receptor editing
(Figs. 2 and 5). One clear indication of receptor editing was
the appearance of B cells bearing both the Tg heavy chain,
as detected with anti-IgDa, and endogenously encoded
light chains, detected with l chain–specific antibody (Fig. 7
A, and reference 49). The increase in the percentages of
“edited” cells was the result of an increase in the total num-
ber of these cells in the lymphoid organs (Table 1). Thus,
Bcl-2 overexpression apparently enhanced receptor editing
or allowed survival of cells that had undergone receptor ed-
iting, or both.
Altered Ig-l/k Ratio Suggests that Bcl-2 Overexpression Pro-
motes Receptor Editing. The elevated frequency of nonau-
toreactive B cells in the CDTg/bcl-2 mice could theo-
retically have been the result of expansion or prolonged
survival of B cells in the peripheral lymphoid organs. This
simple explanation would predict that the relative frequen-
cies of B cells bearing endogenous Ig-l and Ig-k light chains
would be the same in both CDTg and CDTg/bcl-2 mice.
To test this notion, we measured the frequencies of Id2 B
cells that expressed k or l light chains. Fig. 8 A shows that
most of the increase in peripheral B cells of the CDTg/bcl-2
mice could be accounted for by an increase in l1 B cells,
suggesting that the bcl-2 transgene influences B cells under-
going light chain gene rearrangement. Interestingly, this ele-
vated l expression was also observed in bcl-2 Tg mice lack-
ing Ig transgenes (Fig. 8 B), which consistently had a
significantly higher percentage (z17%) of l1 B cells com-
pared to non-Tg mice (z6% l1).
Discussion
This study provides insight into the mechanisms by
which Bcl-2 can perturb B cell tolerance. First, we have
found that natural self-proteins expressed on epithelial cells
can mediate B cell tolerance by accelerating cell death
through a Bcl-2–inhibitable pathway. We have also found
that foreign antigens, administered acutely into the perito-
Figure 7. Increased percentage of
IgDa, l1 cells in CDTg mice with
enforced Bcl-2 expression. 3–83md
Tg mice were bred with bcl-2 Tg
mice in the presence (CDTg) or ab-
sence (NDTg) of bone marrow anti-
gen expression. To determine the
extent of receptor editing, lymph
node cells were double stained for
Tg heavy chain (anti-IgDa) and en-
dogenous light chain (anti-l). (A)
Each row illustrates FACSÒ analysis
from independent experiments. (B)
Summary data showing percentage
of IgDa-positive, Id2 cells in both
CDTg and CDTg mice with Bcl-2
overexpression. Data are presented
as mean 6 SEM.
Figure 8. Bcl-2 overexpression increases l/k ratio of B cells in both 3–83
CDTg mice and non-Ig Tg mice. (A) Lymph node cells from CDTg and
CDTg/bcl-2 mice were double stained with anti-IgDa and anti-l antibod-
ies. Percentage of lymph node cells staining positive for IgDa and negative
for l were scored as k positive. (B) Increased percentage of l-expressing
B cells in (non-Ig Tg) bcl-2 Tg mice. The percentage of IgM1 cells that
were also l positive was determined. Data presented as mean 6 SEM.
Numbers above bars reflect number of mice examined.1519 Lang et al.
neal cavity, can cause rapid B cell deletion that is rescued in
an antigen dose-dependent manner by enforced Bcl-2 ex-
pression. Finally, we have made the novel observation that
enforced Bcl-2 expression in immature B cells promotes re-
ceptor editing.
Consistent with the notion that tolerance mechanisms dif-
fer in immature and mature B cells, Bcl-2 overexpression
was able to abrogate peripheral B cell tolerance, while only
subtly altering central B cell tolerance. The ability of Bcl-2
to confer protection from deletion induced by peripherally
expressed membrane self-antigen suggests that mature, au-
toreactive B cells are tolerized by apoptosis induction. These
results are partly in agreement with the studies of Honjo’s
group (15, 46), who studied the effects of intraperitoneal in-
jections of antiimmunoglobulins and self-erythrocytes, rather
than foreign antigens, on peritoneal B cells that were largely
of the B-1 lineage. The signals regulating apoptosis and im-
mune tolerance in B-1 and B-2 subsets are likely to differ
(5, 6, 18, 60). In our 3–83 Tg mice, the Id1 B cells, includ-
ing those in the peritoneal cavity, are almost entirely B-2 B
cells. Thus, our data are clear evidence for deletion of peri-
toneal B-2 B cells upon antigen encounter in vivo, which
is inhibited by Bcl-2 overexpression in a dose-dependent
manner. No such dose dependence was found in the study
by Nisitani et al. (46), but analogous results have been ob-
tained in bcl-2 transfected WEHI-231 cells in which anti-
IgM–mediated death could be blocked at low but not high
antibody dose (43). These differences may reflect a differ-
ence in the density of tolerogenic antigen expression, in
BCR affinity for antigen, or in the relative tolerance sus-
ceptibility of B-1 and B-2 B cells.
Similar to the results with acute antigen administration,
peripheral B cells tolerized by chronic exposure to natural
autoantigen were variably rescued by enforced Bcl-2 over-
expression. Furthermore, the extent of rescue afforded by the
Bcl-2 transgene appeared to be inversely correlated with the
degree of deletion in its absence: in MT-Kb mice, which
normally show complete deletion of Id1 B cells from lymph
nodes, enforced Bcl-2 only slightly inhibited deletion, whereas
in the KerIV-Kb mice, which may express lower amounts
of Kb in a relatively small subset of epithelial cells and in
which autoreactive B cells are eliminated at a slower pace
than in MT-Kb mice, B cell elimination was fully abro-
gated by Bcl-2. Because in this study the autoantigen and
antibody receptor were kept constant, and only the nature
and anatomical location of the antigenic stimulus were al-
tered, the variable outcomes of Bcl-2 overexpression ap-
pear to be real effects, dependent on antigen density, con-
centration, in vivo location, or the developmental state of
the B cell at time of antigen encounter. These results seem
at odds with the paradigm developed from genetic studies
in Caenorhabditis elegans that places the action of the nema-
tode Bcl-2 homologue ced-9 at a distal point in the death
signaling cascade (61). If this were also true in B cells, one
might predict that Bcl-2 should protect from apoptosis
over a wide range of antigen doses. It is therefore possible
that the function of Bcl-2 is involved with the downstream
integration of certain BCR signals. As Bcl-2 can titrate the
death activity of heterodimerization partners, such as Bax
(62–64), it is possible that the activity or quantity of these
molecules can be affected by antigen signaling. It is inter-
esting in this regard that Bcl-2 is subject to inactivation by
inducible serine phosphorylation (65), a process that could
conceivably be influenced by BCR signaling. It will be im-
portant to determine if higher doses of Bcl-2 can provide
protection at higher antigen dose, or if cell death regulators
distinct from Bcl-2 become limiting. It is interesting to note
in this regard that in one study combined transgene expres-
sion of Bcl-2 and Bcl-xL had an additive, but still incom-
plete, effect in protection from anti-IgD–mediated B cell
elimination (66). An alternative interpretation of our data is
that strong tolerogenic signals through the BCR activate
both Bcl-2–inhibitable and Bcl-2–resistant death pathways,
whereas weaker tolerance signals activate only Bcl-2–inhib-
itable death pathways.
The observed weak or negligible effect of Bcl-2 overex-
pression on the rescue from the bone marrow of autoreac-
tive B cells is in agreement with the study of Hartley et al.
(9), who showed that Bcl-2 could delay turnover and per-
mit limited peripheralization of immature autoreactive B cells,
but could not promote their continued development to
maturity. Young et al. have shown that Bcl-2 expression
permits ectoptic accumulation of pre–B cells in the spleen
(67). In RAG-sufficient mice, these peripheral, immature
B cells are presumably capable of undergoing receptor edit-
ing even in response to antigens expressed exclusively in the
periphery. This suggestion is supported by the upregulation
of RAG-2 messenger RNA levels in spleens of CDTg/bcl-
2/RAG-12/2 mice, which have a significant population of
these immature B2201 cells (data not shown), and by the
appearance of Id2, IgM1 B cells in spleens of 3–83/MT-
Kb/bcl-2 mice (Fig. 1 C). These Id2, IgM1 cells express Tg
heavy chain (data not shown) and are presumed to be the
product of receptor editing. Collectively, these data show
that Bcl-2 overexpression can manifest varying tolerance
phenotypes depending on the maturational stage at which
the B cell encounters autoantigen, promoting receptor ed-
iting in immature cells, and rescuing functional, mature
cells from apoptosis.
How might Bcl-2 promote receptor editing? The ability
of Bcl-2 to permit elevated steady-state numbers of imma-
ture and mature cells cannot alone explain the increased
proportion of l1 B cells because increased numbers of cells
undergoing editing, or surviving after editing, would not
be expected to alter the Ig light chain l/k ratio. A more
likely explanation is that the extended lifespan of autoreac-
tive bone marrow B cells that is conferred by the bcl-2 trans-
gene may provide an extended time window per cell for
light chain gene rearrangement. The current models of mu-
rine light chain rearrangement suggest that l rearrange-
ments generally follow k rearrangement by z24 h (68),
and that most cells that turn over in the bone marrow do so
before l rearrangements are complete (69). This so-called
crash-factor (70) suggests that mouse B cells normally have
too little time to take full advantage of potential l rear-
rangements that could rescue nonfunctional or autoreactive1520 Effect of Bcl-2 Overexpression on Immature and Mature B Cell Tolerance
B cells. We propose that the bcl-2 transgene expression al-
lows autoreactive B cells more potential rearrangement at-
tempts, promoting the development of more nonautoreac-
tive B cells bearing “edited” BCRs. This is consistent with
data concerning transgene-driven Bcl-2 overexpression in
thymocytes in which positive selection is enhanced as a re-
sult of increased endogenous TCR rearrangements, presum-
ably due to the increased lifespan of the double-positive
thymocytes expressing the bcl-2 transgene (1). The finding
that Eu–bcl-2-22 Tg mice have consistently high percent-
ages of l1 B cells suggests that receptor editing is enhanced
even in the absence of antibody transgenes. Data from
Rolink et al. have indicated that the Em–bcl-2-22 transgene
prolongs in vitro survival of B cells undergoing light chain
gene rearrangement resulting in high l/k ratios in cultured B
cells (71).
One implication of our study is that altered or defective
apoptosis in B cells encountering self-antigen in the periph-
ery could provide a pool of potentially functional autoreac-
tive B cells. In this study we have observed that the cells
rescued from elimination by enforced Bcl-2 expression could
sometimes also acquire functional reactivity. Further studies
are needed to fully establish their functional capacity, but
these results further suggest that although multiple inde-
pendent levels of regulation are available to limit autoreac-
tivity at each step in differentiation, tolerance to certain au-
toantigens may be definitively abrogated by a Bcl-2–
inhibitable pathway.
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